×
Request Free Sample ×
Artificial Heart Market Research Report - Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Artificial Heart Market

ID: MRFR/HC/6513-HCR
90 Pages
Rahul Gotadki
October 2025

Artificial Heart Market Research Report Information by Type (Heart-Lung Machine, Mechanical Heart, Total Artificial Hearts, Ventricular Assist Devices (VADs)), End User (Hospitals & Clinics, Specialty Centers) and Region (Americas, Europe, Asia-Pacific, Middle East Africa) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Artificial Heart Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Artificial Heart Market Summary

The Global Artificial Heart Market is projected to grow from 5 USD Billion in 2024 to 7.47 USD Billion by 2032.

Key Market Trends & Highlights

Artificial Heart Market Key Trends and Highlights

  • The market is expected to experience a compound annual growth rate (CAGR) of 3.71% from 2025 to 2032.
  • By 2035, the market valuation is anticipated to reach 7.47 USD Billion, reflecting a steady increase.
  • In 2024, the market is valued at 5 USD Billion, indicating a robust foundation for future growth.
  • Growing adoption of artificial hearts due to advancements in medical technology is a major market driver.

Market Size & Forecast

2024 Market Size 5 (USD Billion)
2035 Market Size 7.47 (USD Billion)
CAGR (2025-2035) 3.71%

Major Players

SynCardia Systems, CryoLife, LLC, ABIOMED, CARMAT, Abbott, Cleveland Heart Inc., Thoratec Corporation

Artificial Heart Market Trends

Drivers- the high increase in market demand of the artificial heart is due to the highly increased cardiovascular disorder among the population along with the increase in the aging population suffering from final stage heart failure. People engaging themselves in smoking along with reimbursement policies so implemented drives up the artificial heart valve market rate and its market value. People developing a high risk of heart complications increase the market growth of artificial heart.

Opportunities- medical device manufacturer is the lucrative opportunity that helps in driving up market growth. Some of the market drivers are an adaptation of new healthcare technology along with taking government initiatives to increase the opportunities of the market. Increased unavailability of favorable insurance policies widens up the opportunities for expanding the market growth of artificial heart.

Challenges- prevalence of HVD globally and regionally and certain regulatory approvals is the challenging factor towards the market growth.

Cumulative growth- the presence of high market value of high USD and high CAGR projects at a high rate covering large market share.

Restraints- strict rules so imposed by the government and the regulatory scenario so imposed as per the FDA policies are the factors that act as a restraining factor affecting the growth of the market. High costs of artificial heart valves along with the high treatment facilities and the regulations so imposed spoils up the market growth.

Artificial Heart Market Drivers

Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases globally is a primary driver for the Global Artificial Heart Market Industry. As heart-related ailments continue to escalate, the demand for advanced cardiac solutions, including artificial hearts, is likely to rise. In 2024, the market is projected to reach 5 USD Billion, reflecting the urgent need for innovative treatments. This trend is expected to persist as the World Health Organization indicates that cardiovascular diseases remain the leading cause of death worldwide. Consequently, healthcare systems are compelled to invest in artificial heart technologies to address this growing health crisis.

Market Segment Insights

Artificial Heart Market Type Insights

globally and regionally, the Artificial Heart Market has been classified into type and end-user. As per the type, the market is classified into the heart-lung machine and mechanical heart. The mechanical heart is further classified into total artificial hearts and ventricular assist devices.

 The mechanical heart part projects at a high CAGR value during the market forecast period which contributes much more to the rise in market demand. Based on the end-users, the heart valve market is divided into hospitals and clinics and some healthcare centers, and many more.

Globally, the types of artificial heart valves expand to the region of America, Europe, Asia Pacific, some of the Middle East, and African regions. The Artificial Heart Market also expands to the regions of North America and some of Latin America areas where their region of North America includes the region of the United States and Canada.

The market expanded to the European region and is divided into Western Europe and Eastern Europe. The Western European region includes some of the areas of Germany, France, Italian areas, the United Kingdom, Spain, and other regions of Western Europe.

 The market in the Asia Pacific market is divided into Japan, China, India, the South Korean region, Australia, and the rest of the Asia Pacific region.

Artificial Heart Market Technology Insights

due to advancement in technology advanced heart surgeries were used. It led to the invention of different types of artificial heart valves which functioned uniquely. Technology arouses awareness about the diagnosis facilities and the treatments. Technology led to the introduction of an innovative new artificial heart of low costs. The artificial heart cost and the cost of the artificial heart valve were not that huge.

Get more detailed insights about Artificial Heart Market
Request Free Sample

Key Companies in the Artificial Heart Market market include

Industry Developments

  • Q2 2024: SynCardia Announces FDA Approval for Next-Generation Total Artificial Heart Market SynCardia Systems received FDA approval for its next-generation Total Artificial Heart Market, designed to improve patient outcomes and device durability. The approval marks a significant milestone for the company and expands treatment options for patients with end-stage heart failure.
  • Q1 2024: Carmat Receives CE Mark Extension for Aeson Artificial Heart Market Carmat announced that it has received an extension of its CE Mark for the Aeson artificial heart, allowing continued commercial sales and use in European markets. The extension supports ongoing adoption of the device for patients with advanced heart failure.
  • Q2 2024: Carmat Resumes Aeson Artificial Heart Market Production After Manufacturing Suspension Carmat resumed production of its Aeson artificial heart following a temporary suspension due to quality control issues. The company implemented corrective actions and received regulatory clearance to restart manufacturing and distribution.
  • Q2 2024: SynCardia Systems Appoints New CEO to Drive Global Expansion SynCardia Systems announced the appointment of a new Chief Executive Officer, aiming to accelerate the company's global expansion and commercialization of its artificial heart technologies.
  • Q1 2024: Carmat Raises €30 Million to Fund Artificial Heart Market Commercialization Carmat completed a €30 million funding round to support the commercialization and scale-up of its Aeson artificial heart in Europe and other markets.
  • Q2 2024: Carmat Signs Distribution Agreement for Aeson Artificial Heart Market in Italy Carmat entered into a distribution agreement with a leading Italian medical device distributor to expand the availability of the Aeson artificial heart in Italy.
  • Q1 2024: FDA Grants Breakthrough Device Designation to BiVACOR Total Artificial Heart Market The FDA granted Breakthrough Device Designation to BiVACOR's Total Artificial Heart Market, recognizing its potential to provide more effective treatment for patients with severe heart failure.
  • Q2 2024: BiVACOR Announces First Human Implantation of Total Artificial Heart Market in U.S. Clinical Trial BiVACOR announced the successful first human implantation of its Total Artificial Heart Market as part of a U.S. clinical trial, marking a major milestone in the development of next-generation artificial heart technology.
  • Q2 2024: Carmat Opens New Manufacturing Facility for Aeson Artificial Heart Market Carmat inaugurated a new manufacturing facility dedicated to the production of its Aeson artificial heart, aiming to increase capacity and meet growing demand in Europe.
  • Q1 2024: SynCardia Systems Expands Distribution Network in Asia-Pacific SynCardia Systems announced the expansion of its distribution network in the Asia-Pacific region, partnering with local medical device companies to increase access to its Total Artificial Heart Market.
  • Q2 2024: Carmat Signs Strategic Partnership with Leading U.S. Cardiac Center Carmat entered into a strategic partnership with a major U.S. cardiac center to advance clinical research and adoption of the Aeson artificial heart in the United States.
  • Q1 2024: BiVACOR Secures $22 Million in Series B Funding to Advance Artificial Heart Market Development BiVACOR raised $22 million in Series B funding to accelerate the development and clinical testing of its Total Artificial Heart Market, supporting ongoing trials and regulatory submissions.

Future Outlook

Artificial Heart Market Future Outlook

The Global Artificial Heart Market is projected to grow at a 3.71% CAGR from 2024 to 2032, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

New opportunities lie in:

  • Develop innovative biocompatible materials for enhanced heart longevity.
  • Expand telemedicine solutions for remote monitoring of artificial heart patients.
  • Invest in partnerships with hospitals for integrated care pathways and patient education.

By 2035, the market is expected to exhibit robust growth, reflecting advancements and increased adoption of artificial heart technologies.

Market Segmentation

Artificial Heart Market Industry Developments

Q2 2024: SynCardia Announces FDA Approval for Next-Generation Total Artificial Heart
Q1 2024: Carmat Receives CE Mark Extension for Aeson Artificial Heart
Q2 2024: Carmat Resumes Aeson Artificial Heart Production After Manufacturing Suspension
Q2 2024: SynCardia Systems Appoints New CEO to Drive Global Expansion
Q1 2024: Carmat Raises €30 Million to Fund Artificial Heart Commercialization
Q2 2024: Carmat Signs Distribution Agreement for Aeson Artificial Heart in Italy
Q1 2024: FDA Grants Breakthrough Device Designation to BiVACOR Total Artificial Heart
Q2 2024: BiVACOR Announces First Human Implantation of Total Artificial Heart in U.S. Clinical Trial
Q2 2024: Carmat Opens New Manufacturing Facility for Aeson Artificial Heart
Q1 2024: SynCardia Systems Expands Distribution Network in Asia-Pacific
Q2 2024: Carmat Signs Strategic Partnership with Leading U.S. Cardiac Center
Q1 2024: BiVACOR Secures $22 Million in Series B Funding to Advance Artificial Heart Development

Report Scope

Report Attribute/Metric Details
  Market Size   USD 5 Billion
  CAGR   14.30%
  Base Year 2023
  Forecast Period   2023-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   SynCardia Systems, LLC, BiVACOR Inc., CARMAT, Cleveland Heart, Inc., ABIOMED, CryoLife, Inc., Abbott, and Thoratec Corporation
  Key Market Opportunities   Medical device manufacturer
  Key Market Drivers ·  Adaptation of healthcare technology ·  Government initiatives to increase the healthcare quality ·  Availability of favorable insurance policies

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What was the valuation in 2030?

The valuation was USD 4.98 billion.

What is the predicted CAGR for the Artificial Heart Market for the forecast period (2022-2030)?

The predicted CAGR would be 14.3%.

What could slow down market growth?

The high cost of the procedure and regulations regarding the process can slow down the growth.

Which type to lead the market?

The mechanical heart segment has the chance to record a higher CAGR.

Which region would take charge of the artificial heart market?

The Americas market would dominate the global field.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓